Home » Stocks » CRNX

Crinetics Pharmaceuticals, Inc. (CRNX)

Stock Price: $15.09 USD 0.88 (6.19%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Market Cap 467.83M
Revenue (ttm) 392,000
Net Income (ttm) -66.72M
Shares Out 32.89M
EPS (ttm) -2.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $15.09
Previous Close $14.21
Change ($) 0.88
Change (%) 6.19%
Day's Open 14.52
Day's Range 14.53 - 15.10
Day's Volume 352,362
52-Week Range 11.52 - 24.18

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

- Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 -

GlobeNewsWire - 1 month ago

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of Dec...

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization...

GlobeNewsWire - 2 months ago

Webinar Being Held on Friday, November 20th @ 11:00 am Eastern Time Webinar Being Held on Friday, November 20th @ 11:00 am Eastern Time

Zacks Investment Research - 2 months ago

Crinetics Pharmaceuticals (CRNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlobeNewsWire - 2 months ago

Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trial s of oral paltusotine for the treatment of acromegaly

GlobeNewsWire - 2 months ago

ACROBAT Edge Results Showed Maintenance of IGF-1 Suppression with Paltusotine After Switching from Depot Somatostatin Receptor Ligand Monotherapy  

GlobeNewsWire - 3 months ago

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializat...

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializat...

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of Septembe...

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializat...

Seeking Alpha - 4 months ago

Crinetics Pharmaceuticals (CRNX) is a clinical stage company focused on in house synthesis of novel molecules for rare endocrine diseases.

GlobeNewsWire - 5 months ago

Paltusotine received Orphan Drug Designation for the treatment of acromegaly

GlobeNewsWire - 6 months ago

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializati...

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Crinetics Pharmaceuticals, Inc. (CRNX).

GlobeNewsWire - 7 months ago

28 patients have completed the open-label Edge trial measuring IGF-1 levels after 13 weeks of treatment when patients with acromegaly were switched to once daily oral paltusotine from commerci...

GlobeNewsWire - 7 months ago

SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializatio...

Zacks Investment Research - 8 months ago

Crinetics Pharmaceuticals (CRNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 8 months ago

Reported positive interim results for the ACROBAT Edge Phase 2 trial of oral paltusotine in the treatment of acromegaly

GlobeNewsWire - 9 months ago

SAN DIEGO, April 17, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercializat...

Zacks Investment Research - 9 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

GlobeNewsWire - 9 months ago

SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercializat...

GlobeNewsWire - 9 months ago

SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercializat...

GlobeNewsWire - 9 months ago

SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercializa...

The Motley Fool - 10 months ago

The coronavirus induced sell-off has created a number of attractive buying opportunities.

Other stocks mentioned: ABBV, AGEN, APHA, BCEL, BCYC, BMY, CPRX, FOLD, GWPH, OGI, PFE, RCUS, SRPT
Zacks Investment Research - 10 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

The Motley Fool - 10 months ago

These relative newcomers to the landscape of publicly-traded biotech stocks could be big winners for early shareholders.

Other stocks mentioned: BCEL
Zacks Investment Research - 1 year ago

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -11.11% and 51.65%, respectively, for the quarter ended September 2019.

Zacks Investment Research - 1 year ago

Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 1 year ago

SAN DIEGO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializat...

Zacks Investment Research - 1 year ago

Crinetics Pharmaceuticals (CRNX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

GlobeNewsWire - 1 year ago

SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercializat...

Zacks Investment Research - 1 year ago

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -13.33% and -100.00%, respectively, for the quarter ended June 2019.

About CRNX

Crinetics Pharmaceuticals, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendoc... [Read more...]

Industry
Biotechnology
IPO Date
Jul 18, 2018
CEO
R. Scott Struthers
Employees
68
Stock Exchange
NASDAQ
Ticker Symbol
CRNX
Full Company Profile

Financial Performance

In 2019, CRNX's revenue was $1.19 million, a decrease of -50.86% compared to the previous year's $2.43 million. Losses were -$50.42 million, 86.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for CRNX stock is "Buy." The 12-month stock price forecast is 33.60, which is an increase of 122.66% from the latest price.

Price Target
$33.60
(122.66% upside)
Analyst Consensus: Buy